OptimizeRx Co. (NASDAQ:OPRX) CEO Buys $100,200.00 in Stock

OptimizeRx Co. (NASDAQ:OPRX) CEO William J. Febbo acquired 20,000 shares of OptimizeRx stock in a transaction dated Thursday, December 12th. The stock was purchased at an average price of $5.01 per share, for a total transaction of $100,200.00. Following the completion of the acquisition, the chief executive officer now directly owns 601,253 shares in the company, valued at approximately $3,012,277.53. This represents a 3.44 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

OptimizeRx Trading Down 8.6 %

OPRX opened at $4.78 on Thursday. The firm has a market cap of $88.05 million, a price-to-earnings ratio of -3.59 and a beta of 1.34. OptimizeRx Co. has a 52 week low of $3.78 and a 52 week high of $16.65. The business’s 50 day moving average is $5.44 and its two-hundred day moving average is $7.89. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 0.29.

Institutional Trading of OptimizeRx

Several institutional investors and hedge funds have recently bought and sold shares of the business. Bank of New York Mellon Corp increased its stake in OptimizeRx by 9.9% in the second quarter. Bank of New York Mellon Corp now owns 111,719 shares of the company’s stock valued at $1,117,000 after purchasing an additional 10,041 shares during the period. Summit Securities Group LLC purchased a new stake in OptimizeRx during the 2nd quarter valued at approximately $25,000. Legato Capital Management LLC lifted its position in OptimizeRx by 74.0% during the 2nd quarter. Legato Capital Management LLC now owns 59,693 shares of the company’s stock worth $597,000 after acquiring an additional 25,377 shares during the period. Rhumbline Advisers grew its stake in shares of OptimizeRx by 9.2% in the 2nd quarter. Rhumbline Advisers now owns 31,462 shares of the company’s stock valued at $315,000 after purchasing an additional 2,658 shares during the last quarter. Finally, Rice Hall James & Associates LLC increased its holdings in shares of OptimizeRx by 23.5% in the second quarter. Rice Hall James & Associates LLC now owns 496,135 shares of the company’s stock valued at $4,961,000 after purchasing an additional 94,253 shares during the period. Hedge funds and other institutional investors own 76.47% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on OPRX. Royal Bank of Canada cut their price target on OptimizeRx from $14.00 to $7.00 and set an “outperform” rating on the stock in a research note on Thursday, November 14th. William Blair reissued an “outperform” rating on shares of OptimizeRx in a research report on Thursday, November 14th. Barclays lowered their price target on OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating for the company in a report on Thursday, November 14th. Roth Mkm reissued a “buy” rating and set a $16.00 price objective (down previously from $20.00) on shares of OptimizeRx in a report on Thursday, November 14th. Finally, JMP Securities lowered their target price on shares of OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating for the company in a report on Thursday, November 14th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $10.42.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.